WO2009072604A1 - 抗nr10抗体、およびその利用 - Google Patents

抗nr10抗体、およびその利用 Download PDF

Info

Publication number
WO2009072604A1
WO2009072604A1 PCT/JP2008/072152 JP2008072152W WO2009072604A1 WO 2009072604 A1 WO2009072604 A1 WO 2009072604A1 JP 2008072152 W JP2008072152 W JP 2008072152W WO 2009072604 A1 WO2009072604 A1 WO 2009072604A1
Authority
WO
WIPO (PCT)
Prior art keywords
antibody
prevention
useful
treatment
inflammatory diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/072152
Other languages
English (en)
French (fr)
Inventor
Taichi Kuramochi
Keiko Kasutani
Souhei Ohyama
Hiroyuki Tsunoda
Tomoyuki Igawa
Tatsuhiko Tachibana
Hirotaka Shiraiwa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chugai Pharmaceutical Co Ltd
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP2009544736A priority Critical patent/JP5682995B2/ja
Priority to EP08857126.0A priority patent/EP2236604B1/en
Priority to KR1020167016319A priority patent/KR20160074019A/ko
Priority to MX2010006096A priority patent/MX337081B/es
Priority to KR1020167013226A priority patent/KR20160062207A/ko
Priority to KR1020177031058A priority patent/KR101840994B1/ko
Priority to US12/745,781 priority patent/US20110129459A1/en
Priority to EP16172648.4A priority patent/EP3095862B9/en
Priority to CN200880126539.4A priority patent/CN101939424B/zh
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Priority to RU2010127292/10A priority patent/RU2531521C2/ru
Priority to BRPI0821110A priority patent/BRPI0821110B8/pt
Priority to ES08857126.0T priority patent/ES2585480T3/es
Priority to CA2708532A priority patent/CA2708532C/en
Priority to DK08857126.0T priority patent/DK2236604T3/en
Priority to AU2008332271A priority patent/AU2008332271C1/en
Priority to PCT/JP2009/054941 priority patent/WO2010064456A1/ja
Publication of WO2009072604A1 publication Critical patent/WO2009072604A1/ja
Priority to TW098141125A priority patent/TWI432209B/zh
Priority to BRPI0906478A priority patent/BRPI0906478B8/pt
Priority to PCT/JP2009/070376 priority patent/WO2010064697A1/ja
Priority to SI200931302T priority patent/SI2354161T1/sl
Priority to MYPI2010002989A priority patent/MY154715A/en
Priority to CA2710264A priority patent/CA2710264C/en
Priority to DK09830463.7T priority patent/DK2354161T3/en
Priority to CN200980106176.2A priority patent/CN101952318B/zh
Priority to US12/809,138 priority patent/US8575317B2/en
Priority to HRP20151215TT priority patent/HRP20151215T1/hr
Priority to RU2010126078/10A priority patent/RU2487136C2/ru
Priority to EP15172595.9A priority patent/EP2949672A1/en
Priority to JP2010507563A priority patent/JP5139517B2/ja
Priority to HUE09830463A priority patent/HUE025958T2/en
Priority to EP09830463.7A priority patent/EP2354161B1/en
Priority to HK11105170.8A priority patent/HK1151048B/xx
Priority to ES09830463.7T priority patent/ES2552690T3/es
Priority to PL09830463T priority patent/PL2354161T3/pl
Priority to AU2009323249A priority patent/AU2009323249C1/en
Priority to PT98304637T priority patent/PT2354161E/pt
Priority to MX2010007936A priority patent/MX2010007936A/es
Priority to KR1020107014700A priority patent/KR101271323B1/ko
Anticipated expiration legal-status Critical
Priority to US14/047,316 priority patent/US9399680B2/en
Priority to US14/340,883 priority patent/US20150175704A1/en
Priority to US16/560,143 priority patent/US20200002429A1/en
Priority to US17/975,865 priority patent/US20230183363A1/en
Priority to US18/661,829 priority patent/US20240294653A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G01N2333/7155—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

　本発明者らは、ＮＲ１０に対して有効な中和活性を有する抗ＮＲ１０抗体を取得することに成功した。本発明によって提供される抗ＮＲ１０抗体は、例えば、炎症性疾患の治療もしくは予防のための医薬品として有用である。
PCT/JP2008/072152 2007-12-05 2008-12-05 抗nr10抗体、およびその利用 Ceased WO2009072604A1 (ja)

Priority Applications (43)

Application Number Priority Date Filing Date Title
CN200880126539.4A CN101939424B (zh) 2007-12-05 2008-12-05 抗nr10抗体及其应用
KR1020167016319A KR20160074019A (ko) 2007-12-05 2008-12-05 항ｎｒ１０ 항체 및 그의 이용
RU2010127292/10A RU2531521C2 (ru) 2007-12-05 2008-12-05 Антитело против nr10 и его применение
KR1020167013226A KR20160062207A (ko) 2008-12-05 2008-12-05 항ｎｒ１０ 항체 및 그의 이용
KR1020177031058A KR101840994B1 (ko) 2007-12-05 2008-12-05 항ｎｒ１０ 항체 및 그의 이용
US12/745,781 US20110129459A1 (en) 2007-12-05 2008-12-05 Anti-nr10 antibody and use thereof
EP16172648.4A EP3095862B9 (en) 2007-12-05 2008-12-05 Anti-nr10 antibody and use thereof
JP2009544736A JP5682995B2 (ja) 2007-12-05 2008-12-05 抗ｎｒ１０抗体、およびその利用
MX2010006096A MX337081B (es) 2007-12-05 2008-12-05 Anticuerpo anti-nr10 y su uso.
EP08857126.0A EP2236604B1 (en) 2007-12-05 2008-12-05 Anti-nr10 antibody and use thereof
BRPI0821110A BRPI0821110B8 (pt) 2007-12-05 2008-12-05 anticorpo de neutralização de anti-nr10/il31ra, composição farmacêutica compreendendo o referido anticorpo e uso do mesmo
ES08857126.0T ES2585480T3 (es) 2007-12-05 2008-12-05 Anticuerpo anti-NR10 y uso del mismo
CA2708532A CA2708532C (en) 2007-12-05 2008-12-05 Anti-il31ra antibody and use thereof
DK08857126.0T DK2236604T3 (en) 2007-12-05 2008-12-05 The anti-NR10 antibody and use thereof
AU2008332271A AU2008332271C1 (en) 2007-12-05 2008-12-05 Anti-NR10 antibody and use thereof
PCT/JP2009/054941 WO2010064456A1 (ja) 2008-12-05 2009-03-13 抗nr10抗体、およびその利用
TW098141125A TWI432209B (zh) 2008-12-05 2009-12-02 Anti-NR10 antibody and its use
KR1020107014700A KR101271323B1 (ko) 2008-12-05 2009-12-04 항ｎｒ１０ 항체 및 그의 이용
MYPI2010002989A MY154715A (en) 2008-12-05 2009-12-04 Anti-nr10 antibody and use thereof
EP09830463.7A EP2354161B1 (en) 2008-12-05 2009-12-04 Anti-nr10 antibody, and use thereof
SI200931302T SI2354161T1 (sl) 2008-12-05 2009-12-04 Anti-NR10 protitelo in njegova uporaba
BRPI0906478A BRPI0906478B8 (pt) 2008-12-05 2009-12-04 anticorpo anti-nr10, seu uso e composição farmacêutica que o compreende
CA2710264A CA2710264C (en) 2007-12-05 2009-12-04 Anti-nr10 antibody and use thereof
DK09830463.7T DK2354161T3 (en) 2008-12-05 2009-12-04 ANTI-NR10 ANTIBODY AND USE THEREOF.
CN200980106176.2A CN101952318B (zh) 2007-12-05 2009-12-04 抗nr10抗体及其应用
US12/809,138 US8575317B2 (en) 2007-12-05 2009-12-04 Anti-NR10 antibody and use thereof
HRP20151215TT HRP20151215T1 (hr) 2007-12-05 2009-12-04 Anti-nr10 protutijela i njihova uporaba
RU2010126078/10A RU2487136C2 (ru) 2008-12-05 2009-12-04 Антитело против nr10 и его применение
EP15172595.9A EP2949672A1 (en) 2008-12-05 2009-12-04 Anti-nr10 antibody, and use thereof
JP2010507563A JP5139517B2 (ja) 2008-12-05 2009-12-04 抗ｎｒ１０抗体、およびその利用
HUE09830463A HUE025958T2 (en) 2007-12-05 2009-12-04 Anti-nr10 antibody, and use thereof
PCT/JP2009/070376 WO2010064697A1 (ja) 2008-12-05 2009-12-04 抗nr10抗体、およびその利用
HK11105170.8A HK1151048B (en) 2008-12-05 2009-12-04 Anti-nr 10 antibody, and use thereof
ES09830463.7T ES2552690T3 (es) 2008-12-05 2009-12-04 Anticuerpo anti-NR10 y uso del mismo
PL09830463T PL2354161T3 (pl) 2008-12-05 2009-12-04 Przeciwciało anty -NR10 i jego zastosowanie
AU2009323249A AU2009323249C1 (en) 2007-12-05 2009-12-04 Anti-NR10 antibody, and use thereof
PT98304637T PT2354161E (pt) 2008-12-05 2009-12-04 Anticorpo anti-nr10, e a sua utilização
MX2010007936A MX2010007936A (es) 2007-12-05 2009-12-04 Anticuerpo anti-nr-10 y su uso.
US14/047,316 US9399680B2 (en) 2007-12-05 2013-10-07 Nucleic acids encoding anti-NR10 antibodies
US14/340,883 US20150175704A1 (en) 2007-12-05 2014-07-25 Anti-nr10 antibody and use thereof
US16/560,143 US20200002429A1 (en) 2007-12-05 2019-09-04 Anti-nr10 antibody and use thereof
US17/975,865 US20230183363A1 (en) 2007-12-05 2022-10-28 Anti-nr10 antibody and use thereof
US18/661,829 US20240294653A1 (en) 2007-12-05 2024-05-13 Anti-nr10 antibody and use thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2007315143 2007-12-05
JP2007-315143 2007-12-05
JP2008247425 2008-09-26
JP2008-247425 2008-09-26

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US12/745,781 A-371-Of-International US20110129459A1 (en) 2007-12-05 2008-12-05 Anti-nr10 antibody and use thereof
US14/340,883 Continuation US20150175704A1 (en) 2007-12-05 2014-07-25 Anti-nr10 antibody and use thereof

Publications (1)

Publication Number Publication Date
WO2009072604A1 true WO2009072604A1 (ja) 2009-06-11

Family

ID=40717782

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/072152 Ceased WO2009072604A1 (ja) 2007-12-05 2008-12-05 抗nr10抗体、およびその利用

Country Status (17)

Country Link
US (7) US20110129459A1 (ja)
EP (2) EP2236604B1 (ja)
JP (1) JP5682995B2 (ja)
KR (3) KR101643005B1 (ja)
CN (2) CN101939424B (ja)
AU (2) AU2008332271C1 (ja)
BR (1) BRPI0821110B8 (ja)
CA (2) CA2708532C (ja)
DK (1) DK2236604T3 (ja)
ES (2) ES2834741T3 (ja)
HR (1) HRP20151215T1 (ja)
HU (1) HUE025958T2 (ja)
MX (2) MX337081B (ja)
MY (1) MY177564A (ja)
RU (1) RU2531521C2 (ja)
TW (2) TWI548418B (ja)
WO (1) WO2009072604A1 (ja)

Cited By (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101952318A (zh) * 2007-12-05 2011-01-19 中外制药株式会社 抗nr10抗体及其应用
WO2011055550A1 (ja) 2009-11-05 2011-05-12 国立大学法人大阪大学 自己免疫疾患又はアレルギー治療剤とそのスクリーニング方法
WO2011090088A1 (ja) 2010-01-20 2011-07-28 中外製薬株式会社 安定化抗体含有溶液製剤
WO2011143318A3 (en) * 2010-05-11 2012-01-05 Aveo Pharmaceuticals, Inc. Anti-fgfr2 antibodies
JPWO2010064697A1 (ja) * 2008-12-05 2012-05-10 中外製薬株式会社 抗ｎｒ１０抗体、およびその利用
WO2012091124A1 (ja) 2010-12-28 2012-07-05 中外製薬株式会社 動物細胞の培養方法
EP2354161A4 (en) * 2008-12-05 2013-01-02 Chugai Pharmaceutical Co Ltd ANTIBODY AGAINST NR10 AND APPLICATION THEREOF
WO2013012022A1 (ja) 2011-07-19 2013-01-24 中外製薬株式会社 アルギニンアミドまたはその類似化合物を含む安定なタンパク質含有製剤
WO2013031237A1 (en) 2011-09-01 2013-03-07 Chugai Seiyaku Kabushiki Kaisha Method for preparing a composition comprising highly concentrated antibodies by ultrafiltration
US8431127B2 (en) 2007-12-05 2013-04-30 Chugai Seiyaku Kabushiki Kaisha Method for treating pruritus comprising administering an NR10 antagonist
JPWO2011108714A1 (ja) * 2010-03-04 2013-06-27 中外製薬株式会社 抗体定常領域改変体
US8562991B2 (en) 2008-09-26 2013-10-22 Chugai Seiyaku Kabushiki Kaisha Antibody molecules that bind to IL-6 receptor
US9028821B2 (en) 2006-06-08 2015-05-12 Chugai Seiyaku Kabushiki Kaisha Method of treating an inflammatory disease comprising administering an NR 10 antibody antagonist
WO2015099165A1 (ja) 2013-12-27 2015-07-02 中外製薬株式会社 等電点の低い抗体の精製方法
US9096651B2 (en) 2007-09-26 2015-08-04 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in CDR
US9228017B2 (en) 2009-03-19 2016-01-05 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
US9670269B2 (en) 2006-03-31 2017-06-06 Chugai Seiyaku Kabushiki Kaisha Methods of modifying antibodies for purification of bispecific antibodies
US9688762B2 (en) 2007-09-26 2017-06-27 Chugai Sciyaku Kabushiki Kaisha Modified antibody constant region
US9868948B2 (en) 2008-04-11 2018-01-16 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
US10011858B2 (en) 2005-03-31 2018-07-03 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
US10150808B2 (en) 2009-09-24 2018-12-11 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant regions
JP2019504060A (ja) * 2016-01-08 2019-02-14 オンコバイオロジクス，インコーポレイティド モノクローナル抗体のアイソフォームを分離するための方法
US10253091B2 (en) 2009-03-19 2019-04-09 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
WO2019225568A1 (ja) 2018-05-21 2019-11-28 中外製薬株式会社 ガラス容器に封入された凍結乾燥製剤
WO2019230725A1 (ja) 2018-05-28 2019-12-05 中外製薬株式会社 充填ノズル
US10544227B2 (en) 2015-04-14 2020-01-28 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition for prevention and/or treatment of atopic dermatitis comprising IL-31 antagonist as active ingredient
US10604561B2 (en) 2016-09-16 2020-03-31 Chugai Seiyaku Kabushiki Kaisha Anti-dengue virus antibodies, polypeptides containing variant Fc regions, and methods of use
US10774148B2 (en) 2015-02-27 2020-09-15 Chugai Seiyaku Kabushiki Kaisha Composition for treating IL-6-related diseases
JP6845973B1 (ja) * 2019-11-20 2021-03-24 中外製薬株式会社 抗体含有製剤
US11046784B2 (en) 2006-03-31 2021-06-29 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
US11124576B2 (en) 2013-09-27 2021-09-21 Chungai Seiyaku Kabushiki Kaisha Method for producing polypeptide heteromultimer
US11142587B2 (en) 2015-04-01 2021-10-12 Chugai Seiyaku Kabushiki Kaisha Method for producing polypeptide hetero-oligomer
WO2022025030A1 (ja) 2020-07-28 2022-02-03 中外製薬株式会社 新規改変型抗体を含む、針シールドを備えた針付プレフィルドシリンジ製剤
WO2022049614A1 (ja) 2020-09-01 2022-03-10 中外製薬株式会社 Ｉｌ－３１アンタゴニストを有効成分として含有する、透析そう痒症の予防用及び／又は治療用医薬組成物
EP4056993A1 (en) 2014-08-20 2022-09-14 Chugai Seiyaku Kabushiki Kaisha Method for measuring viscosity of protein solution
WO2023058723A1 (ja) 2021-10-08 2023-04-13 中外製薬株式会社 プレフィルドシリンジ製剤の調製方法
US11649262B2 (en) 2015-12-28 2023-05-16 Chugai Seiyaku Kabushiki Kaisha Method for promoting efficiency of purification of Fc region-containing polypeptide
JPWO2023120561A1 (ja) * 2021-12-22 2023-06-29
WO2023210670A1 (ja) 2022-04-26 2023-11-02 中外製薬株式会社 医薬製剤含有フィルター内蔵シリンジ
US11851486B2 (en) 2017-05-02 2023-12-26 National Center Of Neurology And Psychiatry Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils
US11891434B2 (en) 2010-11-30 2024-02-06 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
US11891432B2 (en) 2018-03-15 2024-02-06 Chugai Seiyaku Kabushiki Kaisha Anti-dengue virus antibodies having cross-reactivity to Zika virus and methods of use
WO2024214811A1 (ja) 2023-04-14 2024-10-17 中外製薬株式会社 タンパク質含有医薬製剤の安定化方法
US12558423B2 (en) 2020-05-29 2026-02-24 Chugai Seiyaku Kabushiki Kaisha Antibody-containing formulation

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6129956B2 (ja) * 2012-05-09 2017-05-17 イーライ リリー アンド カンパニー 抗ｃ−Ｍｅｔ抗体
PL3489261T3 (pl) 2012-08-24 2021-08-16 The Regents Of The University Of California Przeciwciała i szczepionki do stosowania w leczeniu nowotworów z ekspresją ROR1 i w hamowaniu przerzutu
JP6668345B2 (ja) 2014-11-21 2020-03-18 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 修飾された重鎖定常領域を含む抗体
MY189836A (en) 2014-11-21 2022-03-11 Bristol Myers Squibb Co Antibodies against cd73 and uses thereof
CN105331703B (zh) * 2015-11-16 2018-08-17 中国农业科学院北京畜牧兽医研究所 一种鉴定或辅助鉴定猪100kg体重眼肌面积的方法及其专用试剂盒
IL299099B2 (en) 2016-06-27 2025-07-01 Univ California Cancer treatment combinations
CN113637073B (zh) * 2020-05-11 2024-04-12 上海赛比曼生物科技有限公司 Bcma抗体及其制备和应用
TWI905235B (zh) * 2020-07-29 2025-11-21 美商當康生物科技有限公司 抗cd93之構築體及其用途
US20220411518A1 (en) * 2021-04-07 2022-12-29 Galderma Holding S.A. Treatments for prurigo nodularis
IL311066A (en) * 2021-08-30 2024-04-01 Galderma Holding SA Treatments for atopic dermatitis

Citations (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
EP0058481A1 (en) 1981-02-16 1982-08-25 Zeneca Limited Continuous release pharmaceutical compositions
EP0125023A1 (en) 1983-04-08 1984-11-14 Genentech, Inc. Recombinant immunoglobulin preparations, methods for their preparation, DNA sequences, expression vectors and recombinant host cells therefor
EP0133988A2 (de) 1983-08-02 1985-03-13 Hoechst Aktiengesellschaft Regulatorische Peptide enthaltende pharmazeutische Präparate mit protrahierter Freisetzung und Verfahren zu deren Herstellung
EP0239400A2 (en) 1986-03-27 1987-09-30 Medical Research Council Recombinant antibodies and methods for their production
JPH0159878B2 (ja) 1982-05-21 1989-12-20 Yunibaashitei Obu Karifuorunia
EP0404097A2 (de) 1989-06-22 1990-12-27 BEHRINGWERKE Aktiengesellschaft Bispezifische und oligospezifische, mono- und oligovalente Rezeptoren, ihre Herstellung und Verwendung
US5057313A (en) 1986-02-25 1991-10-15 The Center For Molecular Medicine And Immunology Diagnostic and therapeutic antibody conjugates
WO1992001047A1 (en) 1990-07-10 1992-01-23 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
WO1992003918A1 (en) 1990-08-29 1992-03-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5156840A (en) 1982-03-09 1992-10-20 Cytogen Corporation Amine-containing porphyrin derivatives
WO1992020791A1 (en) 1990-07-10 1992-11-26 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
WO1993006213A1 (en) 1991-09-23 1993-04-01 Medical Research Council Production of chimeric antibodies - a combinatorial approach
WO1993011161A1 (en) 1991-11-25 1993-06-10 Enzon, Inc. Multivalent antigen-binding proteins
WO1993011236A1 (en) 1991-12-02 1993-06-10 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1993019172A1 (en) 1992-03-24 1993-09-30 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
WO1994002602A1 (en) 1992-07-24 1994-02-03 Cell Genesys, Inc. Generation of xenogeneic antibodies
WO1994025585A1 (en) 1993-04-26 1994-11-10 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1995001438A1 (en) 1993-06-30 1995-01-12 Medical Research Council Sbp members with a chemical moiety covalently bound within the binding site; production and selection thereof
WO1995015388A1 (en) 1993-12-03 1995-06-08 Medical Research Council Recombinant binding proteins and peptides
WO1996002576A1 (en) 1994-07-13 1996-02-01 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human interleukin-8
WO1996033735A1 (en) 1995-04-27 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1998013388A1 (en) 1996-09-26 1998-04-02 Chugai Seiyaku Kabushiki Kaisha Antibody against human parathormone related peptides
WO1998046777A1 (fr) 1997-04-11 1998-10-22 Centre National De La Recherche Scientifique (Cnrs) Preparation de recepteurs membranaires a partir de baculovirus extracellulaires
WO2000075314A1 (en) 1999-06-02 2000-12-14 Chugai Research Institute For Molecular Medicine, Inc. Novel hemopoietin receptor protein nr10
WO2003104453A1 (ja) 2002-06-05 2003-12-18 中外製薬株式会社 抗体作製方法
WO2005054467A1 (ja) 2003-12-03 2005-06-16 Chugai Seiyaku Kabushiki Kaisha 哺乳類βアクチンプロモーターを利用した発現系
WO2006070286A2 (en) * 2004-12-28 2006-07-06 Innate Pharma S.A. Monoclonal antibodies against nkg2a

Family Cites Families (119)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59162441U (ja) 1983-04-14 1984-10-31 千代田紙業株式会社 吹込口を有する重包包装
US5260203A (en) * 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US5670373A (en) * 1988-01-22 1997-09-23 Kishimoto; Tadamitsu Antibody to human interleukin-6 receptor
US5322678A (en) 1988-02-17 1994-06-21 Neorx Corporation Alteration of pharmacokinetics of proteins by charge modification
EP0628639B1 (en) * 1991-04-25 1999-06-23 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human interleukin 6 receptor
US6136310A (en) 1991-07-25 2000-10-24 Idec Pharmaceuticals Corporation Recombinant anti-CD4 antibodies for human therapy
JPH0767688B2 (ja) 1992-01-21 1995-07-26 近畿コンクリート工業株式会社 Ｐｃコンクリートパネル
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
BR9204244A (pt) 1992-10-26 1994-05-03 Cofap Ferro fundido cinzento
WO1994012215A1 (en) 1992-12-01 1994-06-09 Protein Design Labs, Inc. Humanized antibodies reactive with l-selectin
IL107742A0 (en) 1993-11-24 1994-02-27 Yeda Res & Dev Chemically-modified binding proteins
DE4419399C1 (de) 1994-06-03 1995-03-09 Gsf Forschungszentrum Umwelt Verfahren zur Herstellung von heterologen bispezifischen Antikörpern
US5945311A (en) 1994-06-03 1999-08-31 GSF--Forschungszentrumfur Umweltund Gesundheit Method for producing heterologous bi-specific antibodies
US8017121B2 (en) * 1994-06-30 2011-09-13 Chugai Seiyaku Kabushika Kaisha Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
PT783893E (pt) 1994-10-07 2012-05-24 Chugai Pharmaceutical Co Ltd Inibição do crescimento anormal das células sinoviais usando antagonistas de il-6 como componente ativo
CN1306963C (zh) 1994-10-21 2007-03-28 岸本忠三 用于治疗il－6产生所致疾病的药物组合物
US5876950A (en) 1995-01-26 1999-03-02 Bristol-Myers Squibb Company Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy
FR2729855A1 (fr) 1995-01-26 1996-08-02 Oreal Utilisation d'un antagoniste de cgrp dans une composition cosmetique, pharmaceutique ou dermatologique et composition obtenue
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
CN1241944C (zh) 1995-09-11 2006-02-15 协和发酵工业株式会社 抗人白介素－5受体α链的抗体
IL127872A0 (en) 1996-07-19 1999-10-28 Amgen Inc Analogs of cationic proteins
US20070059302A1 (en) * 1997-04-07 2007-03-15 Genentech, Inc. Anti-vegf antibodies
US20020187150A1 (en) * 1997-08-15 2002-12-12 Chugai Seiyaku Kabushiki Kaisha Preventive and/or therapeutic agent for systemic lupus erythematosus comprising anti-IL-6 receptor antibody as an active ingredient
JP3992298B2 (ja) * 1997-10-03 2007-10-17 中外製薬株式会社 天然ヒト型化抗体
DK1074268T3 (da) * 1998-03-17 2008-04-28 Chugai Pharmaceutical Co Ltd IL-6-receptorantagonistantistofholdige forebyggende eller terapeutiske midler mod inflammatoriske tarmsygdomme
US6677436B1 (en) 1998-04-03 2004-01-13 Chugai Seiyaku Kabushiki Kaisha Humanized antibody against human tissue factor (TF) and process of production of the humanized antibody
CN101070344A (zh) 1998-04-30 2007-11-14 泰诺士公司 G－csf受体兴奋剂抗体及其筛选方法
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
FR2780062B1 (fr) 1998-06-17 2000-07-28 Rhone Poulenc Rorer Sa Anticorps monoclonaux diriges contre la proteine g3bp, et leurs utilisations
EP1105427A2 (en) 1998-08-17 2001-06-13 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
JP2002531466A (ja) * 1998-12-01 2002-09-24 プロテイン デザイン ラブス， インコーポレイテッド γ−インターフェロンに対するヒト化抗体
WO2000034317A2 (en) 1998-12-08 2000-06-15 Biovation Limited Method for reducing immunogenicity of proteins
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US6972125B2 (en) 1999-02-12 2005-12-06 Genetics Institute, Llc Humanized immunoglobulin reactive with B7-2 and methods of treatment therewith
SK782002A3 (en) * 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
SE9903895D0 (sv) 1999-10-28 1999-10-28 Active Biotech Ab Novel compounds
CZ20023913A3 (cs) 2000-05-03 2003-09-17 Munich Biotech Ag Kationtová diagnostická, zobrazovací a terapeutická činidla spojená s aktivovanými cévními místy
US20030096339A1 (en) * 2000-06-26 2003-05-22 Sprecher Cindy A. Cytokine receptor zcytor17
WO2002036165A1 (fr) * 2000-10-27 2002-05-10 Chugai Seiyaku Kabushiki Kaisha Agent à base d'antagoniste d'il-6, faisant baisser le niveau des mmp-3 dans le sang
AU2002248571B2 (en) 2001-03-07 2007-01-18 Merck Patent Gmbh Expression technology for proteins containing a hybrid isotype antibody moiety
UA80091C2 (en) 2001-04-02 2007-08-27 Chugai Pharmaceutical Co Ltd Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
US20040234524A1 (en) 2001-04-05 2004-11-25 Toshimitsu Uede Anti-osteopontin antibody and use thereof
GEP20074252B (en) 2001-04-13 2007-12-10 Biogen Idec Inc Antibodies to vla-1
CA2451493C (en) 2001-06-22 2016-08-23 Chugai Seiyaku Kabushiki Kaisha Cell growth inhibitors containing anti-glypican 3 antibody
AU2003280410B8 (en) * 2002-01-18 2009-04-23 Zymogenetics, Inc. Cytokine receptor zcytor17 multimers
ATE401390T1 (de) * 2002-01-18 2008-08-15 Zymogenetics Inc Zytokin (zcytor17-ligand)
WO2005056606A2 (en) 2003-12-03 2005-06-23 Xencor, Inc Optimized antibodies that target the epidermal growth factor receptor
WO2003107218A1 (ja) 2002-05-31 2003-12-24 セレスター・レキシコ・サイエンシズ株式会社 相互作用予測装置
AU2003256266A1 (en) 2002-06-12 2003-12-31 Genencor International, Inc. Methods and compositions for milieu-dependent binding of a targeted agent to a target
TW200407335A (en) * 2002-07-22 2004-05-16 Chugai Pharmaceutical Co Ltd Non-neutralizing antibody to inhibit the inactivation of activated protein C
AU2003264009A1 (en) 2002-08-15 2004-03-03 Epitomics, Inc. Humanized rabbit antibodies
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
KR100499989B1 (ko) 2002-12-27 2005-07-07 네오바이오다임 주식회사 아사이알로 α1-산 당단백질에 대한 단일클론 항체, 이 항체를 포함하는 아사이알로 α1-산 당단백질에 대한 단일클론 항체, 이 항체를 포함하는 면역크로마토그래피 스트립 및 이 스트립를 이용한 아사이알로 α1-산 당단백질 측정방법
CA2515081A1 (en) 2003-02-07 2004-08-19 Protein Design Labs, Inc. Amphiregulin antibodies and their use to treat cancer and psoriasis
US20040223970A1 (en) * 2003-02-28 2004-11-11 Daniel Afar Antibodies against SLC15A2 and uses thereof
JP2006521387A (ja) 2003-03-04 2006-09-21 アレクシオン ファーマシューティカルズ， インコーポレイテッド 寛容誘導抗原提示細胞による抗原提示の誘導によって自己免疫疾患を治療する方法
EP1606316A2 (en) 2003-03-24 2005-12-21 ZymoGenetics, Inc. Anti-il-20 antibodies and binding partners and methods of using in inflammation
GB2401040A (en) 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
EP1636264A2 (en) 2003-06-24 2006-03-22 MERCK PATENT GmbH Tumour necrosis factor receptor molecules with reduced immunogenicity
AU2003271174A1 (en) 2003-10-10 2005-04-27 Chugai Seiyaku Kabushiki Kaisha Double specific antibodies substituting for functional protein
WO2005035754A1 (ja) 2003-10-14 2005-04-21 Chugai Seiyaku Kabushiki Kaisha 機能蛋白質を代替する二重特異性抗体
WO2005047327A2 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
AR048210A1 (es) 2003-12-19 2006-04-12 Chugai Pharmaceutical Co Ltd Un agente preventivo para la vasculitis.
MX350383B (es) 2004-01-09 2017-09-04 Pfizer Anticuerpos contra madcam.
EP1737890A2 (en) * 2004-03-24 2007-01-03 Xencor, Inc. Immunoglobulin variants outside the fc region
AR048335A1 (es) 2004-03-24 2006-04-19 Chugai Pharmaceutical Co Ltd Agentes terapeuticos para trastornos del oido interno que contienen un antagonista de il- 6 como un ingrediente activo
AR049390A1 (es) 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
US20060019342A1 (en) * 2004-06-25 2006-01-26 Medimmune, Inc. Increasing the production of recombinant antibodies in mammalian cells by site-directed mutagenesis
CN103172731A (zh) 2004-07-15 2013-06-26 赞科股份有限公司 优化的Fc变体
US20080233131A1 (en) 2004-09-14 2008-09-25 Richard John Stebbings Vaccine
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
WO2006047350A2 (en) 2004-10-21 2006-05-04 Xencor, Inc. IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION
JP5553963B2 (ja) * 2004-10-22 2014-07-23 アムジエン・インコーポレーテツド 組換え抗体をリフォールディングする方法
EP1810035A4 (en) * 2004-11-10 2010-03-17 Macrogenics Inc GENERATION OF FC ANTIBODY REGIONS FOR EFFECTOR FUNCTION
EP1829961A4 (en) 2004-12-22 2008-06-04 Chugai Pharmaceutical Co Ltd METHOD FOR THE PRODUCTION OF AN ANTIBODY USING A CELL WITH HARDENED FUCOSET TRANSPORT FUNCTION
US20090087478A1 (en) 2004-12-27 2009-04-02 Progenics Pharmaceuticals (Nevada), Inc. Orally Deliverable and Anti-Toxin Antibodies and Methods for Making and Using Them
JP4986633B2 (ja) 2005-01-12 2012-07-25 協和発酵キリン株式会社 安定化されたヒトＩｇＧ２およびＩｇＧ３抗体
WO2006076594A2 (en) * 2005-01-12 2006-07-20 Xencor, Inc. Antibodies and fc fusion proteins with altered immunogenicity
JP2008530132A (ja) 2005-02-14 2008-08-07 ザイモジェネティクス， インコーポレイテッド Ｉｌ−３１ｒａアンタゴニストを用いて皮膚障害を治療する方法
EP3050963B1 (en) 2005-03-31 2019-09-18 Chugai Seiyaku Kabushiki Kaisha Process for production of polypeptide by regulation of assembly
CA2603264C (en) * 2005-04-08 2017-03-21 Chugai Seiyaku Kabushiki Kaisha Antibody substituting for function of blood coagulation factor viii
PE20061323A1 (es) 2005-04-29 2007-02-09 Rinat Neuroscience Corp Anticuerpos dirigidos contra el peptido amiloide beta y metodos que utilizan los mismos
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
JP2009510102A (ja) 2005-09-29 2009-03-12 ヴァイラル ロジック システムズ テクノロジー コーポレーション 免疫調節組成物およびその使用
RU2446826C2 (ru) 2005-10-14 2012-04-10 Фукуока Юниверсити Агенты для подавления повреждения трансплантированных островков после трансплантации островков
AR058135A1 (es) 2005-10-21 2008-01-23 Chugai Pharmaceutical Co Ltd Agentes para el tratamiento de cardiopatias
WO2007133816A2 (en) * 2006-01-10 2007-11-22 Zymogenetics, Inc. Methods of treating pain and inflammation in neuronal tissue using il-31ra and osmrb antagonists
HUE028179T2 (en) * 2006-01-12 2016-12-28 Alexion Pharma Inc Antibodies to OX-2 / CD200 and their use
CA2644663A1 (en) 2006-03-23 2007-09-27 Kirin Pharma Kabushiki Kaisha Agonist antibody to human thrombopoietin receptor
RU2429244C2 (ru) * 2006-03-23 2011-09-20 Байоарктик Ньюросайенс Аб Улучшенные селективные в отношении протофибрилл антитела и их применение
ES2892925T3 (es) 2006-03-31 2022-02-07 Chugai Pharmaceutical Co Ltd Métodos para controlar la farmacocinética en sangre de anticuerpos
US9670269B2 (en) 2006-03-31 2017-06-06 Chugai Seiyaku Kabushiki Kaisha Methods of modifying antibodies for purification of bispecific antibodies
EP2025346B1 (en) * 2006-04-07 2016-08-10 Osaka University Muscle regeneration promoter
WO2007142325A1 (ja) 2006-06-08 2007-12-13 Chugai Seiyaku Kabushiki Kaisha 炎症性疾患の予防または治療剤
EP2032602B1 (en) * 2006-06-15 2013-03-27 The Board of Trustees of the University of Arkansas Monoclonal antibodies that selectively recognize methamphetamine and methamphetamine like compounds
US20100034194A1 (en) 2006-10-11 2010-02-11 Siemens Communications Inc. Eliminating unreachable subscribers in voice-over-ip networks
WO2008092117A2 (en) 2007-01-25 2008-07-31 Xencor, Inc. Immunoglobulins with modifications in the fcr binding region
US7919594B2 (en) * 2007-02-14 2011-04-05 Vaccinex, Inc. Human anti-CD100 antibodies
AR065420A1 (es) 2007-02-23 2009-06-03 Schering Corp Anticuerpos anti-il-23 p19 de ingenieria
WO2008114733A1 (ja) * 2007-03-16 2008-09-25 Kyowa Hakko Kirin Co., Ltd. 抗Claudin-4抗体
GB0708002D0 (en) 2007-04-25 2007-06-06 Univ Sheffield Antibodies
EP2155790A1 (en) 2007-05-31 2010-02-24 Genmab A/S Method for extending the half-life of exogenous or endogenous soluble molecules
EP2031064A1 (de) 2007-08-29 2009-03-04 Boehringer Ingelheim Pharma GmbH & Co. KG Verfahren zur Steigerung von Proteintitern
CN101874042B9 (zh) 2007-09-26 2019-01-01 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
AU2008304748C1 (en) 2007-09-26 2014-06-12 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant region
EP2206775B1 (en) 2007-09-26 2016-06-29 Chugai Seiyaku Kabushiki Kaisha Anti-il-6 receptor antibody
KR20150126724A (ko) 2007-09-28 2015-11-12 추가이 세이야쿠 가부시키가이샤 혈장 중 반응속도가 개선된 항-글리피칸-3 항체
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
CA2708532C (en) * 2007-12-05 2018-06-05 Chugai Seiyaku Kabushiki Kaisha Anti-il31ra antibody and use thereof
CN104162155A (zh) 2007-12-05 2014-11-26 中外制药株式会社 搔痒症治疗药
HRP20160855T1 (hr) 2008-02-08 2016-09-23 Medimmune, Llc Anti-ifnar1 protutijela sa smanjenim afinitetom fc liganda
KR102057826B1 (ko) * 2008-04-11 2019-12-20 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복 결합하는 항원 결합 분자
CA2722600C (en) 2008-05-01 2014-01-21 Amgen Inc. Anti-hepcidin antibodies and methods of use
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
TWI682995B (zh) * 2009-03-19 2020-01-21 日商中外製藥股份有限公司 抗體恆定區域改變體
WO2010107110A1 (ja) * 2009-03-19 2010-09-23 中外製薬株式会社 抗体定常領域改変体
US10150808B2 (en) * 2009-09-24 2018-12-11 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant regions
JP5889181B2 (ja) * 2010-03-04 2016-03-22 中外製薬株式会社 抗体定常領域改変体
SG183867A1 (en) 2010-03-11 2012-10-30 Rinat Neuroscience Corp ANTIBODIES WITH pH DEPENDENT ANTIGEN BINDING

Patent Citations (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
EP0058481A1 (en) 1981-02-16 1982-08-25 Zeneca Limited Continuous release pharmaceutical compositions
US5156840A (en) 1982-03-09 1992-10-20 Cytogen Corporation Amine-containing porphyrin derivatives
JPH0159878B2 (ja) 1982-05-21 1989-12-20 Yunibaashitei Obu Karifuorunia
EP0125023A1 (en) 1983-04-08 1984-11-14 Genentech, Inc. Recombinant immunoglobulin preparations, methods for their preparation, DNA sequences, expression vectors and recombinant host cells therefor
EP0133988A2 (de) 1983-08-02 1985-03-13 Hoechst Aktiengesellschaft Regulatorische Peptide enthaltende pharmazeutische Präparate mit protrahierter Freisetzung und Verfahren zu deren Herstellung
US5057313A (en) 1986-02-25 1991-10-15 The Center For Molecular Medicine And Immunology Diagnostic and therapeutic antibody conjugates
EP0239400A2 (en) 1986-03-27 1987-09-30 Medical Research Council Recombinant antibodies and methods for their production
EP0404097A2 (de) 1989-06-22 1990-12-27 BEHRINGWERKE Aktiengesellschaft Bispezifische und oligospezifische, mono- und oligovalente Rezeptoren, ihre Herstellung und Verwendung
WO1992001047A1 (en) 1990-07-10 1992-01-23 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
WO1992020791A1 (en) 1990-07-10 1992-11-26 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
WO1992003918A1 (en) 1990-08-29 1992-03-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1993006213A1 (en) 1991-09-23 1993-04-01 Medical Research Council Production of chimeric antibodies - a combinatorial approach
WO1993011161A1 (en) 1991-11-25 1993-06-10 Enzon, Inc. Multivalent antigen-binding proteins
WO1993011236A1 (en) 1991-12-02 1993-06-10 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1993019172A1 (en) 1992-03-24 1993-09-30 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
WO1994002602A1 (en) 1992-07-24 1994-02-03 Cell Genesys, Inc. Generation of xenogeneic antibodies
WO1994025585A1 (en) 1993-04-26 1994-11-10 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1995001438A1 (en) 1993-06-30 1995-01-12 Medical Research Council Sbp members with a chemical moiety covalently bound within the binding site; production and selection thereof
WO1995015388A1 (en) 1993-12-03 1995-06-08 Medical Research Council Recombinant binding proteins and peptides
WO1996002576A1 (en) 1994-07-13 1996-02-01 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human interleukin-8
WO1996033735A1 (en) 1995-04-27 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1998013388A1 (en) 1996-09-26 1998-04-02 Chugai Seiyaku Kabushiki Kaisha Antibody against human parathormone related peptides
WO1998046777A1 (fr) 1997-04-11 1998-10-22 Centre National De La Recherche Scientifique (Cnrs) Preparation de recepteurs membranaires a partir de baculovirus extracellulaires
WO2000075314A1 (en) 1999-06-02 2000-12-14 Chugai Research Institute For Molecular Medicine, Inc. Novel hemopoietin receptor protein nr10
WO2003104453A1 (ja) 2002-06-05 2003-12-18 中外製薬株式会社 抗体作製方法
WO2005054467A1 (ja) 2003-12-03 2005-06-16 Chugai Seiyaku Kabushiki Kaisha 哺乳類βアクチンプロモーターを利用した発現系
WO2006070286A2 (en) * 2004-12-28 2006-07-06 Innate Pharma S.A. Monoclonal antibodies against nkg2a

Non-Patent Citations (72)

* Cited by examiner, † Cited by third party
Title
"Heterogeneity of Monoclonal Antibodies", JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 97, no. 7, pages 2426 - 2447
ALTSCHUL ET AL., J. MOL. BIOL., vol. 215, 1990, pages 403 - 10
ANAL BIOCHEM., vol. 360, no. 1, 1 January 2007 (2007-01-01), pages 75 - 83
ANN HEMATOL., vol. 76, no. 6, June 1998 (1998-06-01), pages 231 - 48
BETTER ET AL., SCIENCE, vol. 240, 1988, pages 1041 - 1043
BETTER, M.; HORWITZ, A. H., METHODS ENZYMOL., vol. 178, 1989, pages 476 - 496
BETTER, M.; HORWITZ, A. H., METHODS IN ENZYMOLOGY, vol. 178, 1989, pages 476 - 496
BIOCHEM. BIOPHYS. RES. COMMUN., vol. 228, 1996, pages 838 - 45
BIRD, R. E. ET AL., TIBTECH, vol. 9, 1991, pages 132 - 137
BIRD, R. E.; WALKER, B. W., TRENDS BIOTECHNOL., vol. 9, 1991, pages 132 - 137
CANCER RES., vol. 53, no. 4, 15 February 1993 (1993-02-15), pages 851 - 6
CHIRINO AJ. ET AL.: "Minimizing the immunogenicity of protein therapeutics", DRUG DISCOV. TODAY, vol. 9, no. 2, 2004, pages 82 - 90, XP002395255 *
CO, M. S. ET AL., J. IMMUNOL., vol. 152, 1994, pages 2968 - 2976
CO, M.S. ET AL., J. IMMUNOL., vol. 152, 1994, pages 2968 - 2976
DALBADIE-MCFARLAND, G. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 79, 1982, pages 6409 - 13
DILLON SR. ET AL.: "Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice", NAT. IMMUNOL., vol. 5, no. 7, 2004, pages 752 - 760, XP002407998 *
DIVEU C. ET AL.: "GPL, a novel cytokine receptor related to GP130 and leukemia inhibitory factor receptor", J. BIOL. CHEM., vol. 278, no. 50, 2003, pages 49850 - 49859, XP002475880 *
EUR J IMMUNOL., vol. 29, no. 8, August 1999 (1999-08-01), pages 2613 - 24
EWERT S. ET AL.: "Stability improvement of antibodies for extracellular and intracellular applications: CDR grafting to stable frameworks and structure-based framework engineering", METHODS, vol. 34, no. 2, 2004, pages 184 - 199, XP008133067 *
FASEB J., vol. 6, 1992, pages 2422 - 2427
HANES J. ET AL.: "Picomolar affinity antibodies from a fully synthetic naive library selected and evolved by ribosome display", NAT. BIOTECHNOL., vol. 18, no. 12, 2000, pages 1287 - 1292, XP001121946 *
HASHIMOTO-GOTOH, T; MIZUNO, T; OGASAHARA, Y; NAKAGAWA, M.: "An oligodeoxyribonucleotide-directed dual amber method for site-directed mutagenesis", GENE, vol. 152, 1995, pages 271 - 275
HOLLIGER P ET AL., PROC. NATL ACAD. SCI. USA, vol. 90, 1993, pages 6444 - 6448
HOPP, T. P. ET AL., BIOTECHNOLOGY, vol. 6, 1988, pages 1204 - 1210
HUDSON ET AL., J IMMUNOL. METHODS, vol. 231, 1999, pages 177 - 189
HUSTON, J. S. ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol. 85, 1988, pages 5879 - 5883
INT. IMMUNOL., vol. 18, no. 12, December 2006 (2006-12-01), pages 1759 - 69
J ALLERGY CLIN IMMUNOL., vol. 117, no. 2, February 2006 (2006-02-01), pages 418 - 25
J BIOL CHEM, vol. 277, 2002, pages 16831 - 6
J BIOL CHEM, vol. 278, 2003, pages 49850 - 9
J BIOL CHEM., vol. 283, no. 23, 6 June 2008 (2008-06-06), pages 16206 - 15
J PHARM SCI., vol. 97, no. 4, April 2008 (2008-04-01), pages 1414 - 26
J. BIOL. CHEM., vol. 282, no. 3, 19 January 2007 (2007-01-19), pages 1709 - 17
J. EXP. MED., vol. 180, no. 6, 1994, pages 2377 - 2381
J. IMMUNOL., vol. 169, no. 9, 1 November 2002 (2002-11-01), pages 5171 - 80
J. IMMUNOL., vol. 176, no. 1, 1 January 2006 (2006-01-01), pages 346 - 56
KARLIN; ALTSCHUL, PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 5G73 - 7
KOHLER, G.; MILSTEIN, C., METHODS ENZYMOL., vol. 73, 1981, pages 3 - 46
KOHLER. G.; MILSTEIN, C., METHODS ENZYMOL., vol. 73, 1981, pages 3 - 46
KRAMER W; FRITZ HJ: "Oligonucleotide-directed construction of mutations via gapped duplex DNA Methods", ENZYMOL., vol. 154, 1987, pages 350 - 367
KRAMER, W; DRUTSA, V; JANSEN, HW; KRAMER, B; PFLUGFELDER, M; FRITZ, HJ: "The gapped duplex DNA approach to oligonucleotide-directed mutation construction", NUCLEIC ACIDS RES., vol. 12, 1984, pages 9441 - 9456
KUNKEL, TA: "Rapid and efficient site-specific mutagenesis without phenotypic selection", PROC NATL ACAD SCI USA., vol. 82, 1985, pages 488 - 492
LAMOYI, E., METHODS ENZYMOL., vol. 121, 1986, pages 652 - 663
LAMOYI, E., METHODS IN ENZYMOLOGY, vol. 121, 1989, pages 652 - 663
LANGER ET AL., J. BIOMED. MATER. RES., vol. 15, 1981, pages 167 - 277
LANGER, CHEM. TECH., vol. 12, 1982, pages 98 - 105
LEI, S. P. ET AL., J. BACTERIAL., vol. 169, 1987, pages 4379
MARK, D. F. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 81, 1984, pages 5662 - 6
METHODS, vol. 34, no. 4, December 2004 (2004-12-01), pages 468 - 75
MIZUSHIMA ET AL., NUCLEIC ACIDS RES., vol. 18, 1990, pages 5322
MULLIGAN ET AL., NATURE, vol. 277, 1979, pages 108
NAT BIOTECHNOL., vol. 25, no. 12, December 2007 (2007-12-01), pages 1369 - 72
NAT IMMUNOL, vol. 5, 2004, pages 752 - 60
NAT REV IMMUNOL., vol. 7, no. 9, September 2007 (2007-09-01), pages 715 - 25
NAT. BIOTECHNOL., vol. 25, no. 12, December 2007 (2007-12-01), pages 1369 - 72
NUCLEIC ACIDS. RES., vol. 18, no. 17, 1990, pages 5322
PACE ET AL., PROTEIN SCIENCE, vol. 4, 1995, pages 2411 - 2423
PLUCKTHUN, A.; SKERRA, A., METHODS ENZYMOL., vol. 178, 1989, pages 497 - 515
PLUECKTHUN, A.; SKERRA, A., METHODS IN ENZYMOLOGY, vol. 178, 1989, pages 476 - 496
PROC. NATL. ACAD. SCI. U.S.A., vol. 99, no. 26, 2002, pages 16899 - 16903
PROC. NATL. ACAD. SCI. USA., vol. 103, no. 49, 5 December 2006 (2006-12-05), pages 18709 - 14
PROTEIN ENGINEERING, vol. 9, no. 3, 1996, pages 299 - 305
ROUSSEAUX, J. ET AL., METHODS ENZYMOL., vol. 121, 1986, pages 663 - 669
ROUSSEAUX, J. ET AL., METHODS IN ENZYMOLOGY, vol. 121, 1989, pages 663 - 669
SATO, K. ET AL., CANCER RES., vol. 53, 1993, pages 851 - 856
See also references of EP2236604A4
SIDMAN ET AL., BIOPOLYMERS, vol. 22, 1983, pages 547 - 56
TAN PH. ET AL.: "Engineering the isoelectric point of a renal cell carcinoma targeting antibody greatly enhances scFv solubility", IMMUNOTECHNOLOGY, vol. 4, no. 2, 1998, pages 107 - 114, XP004153635 *
WANG, A. ET AL., SCIENCE, vol. 224, 1984, pages 1431 - 3
WARD ET AL., NATURE, vol. 341, 1989, pages 544 - 546
ZOLLER, M. J.; SMITH, M., NUCLEIC ACIDS RES., vol. 10, 1982, pages 6487 - 500
ZOLLER, MJ; SMITH, M.: "Oligonucleotide-directed mutagenesis of DNA fragments cloned into M13 vectors", METHODS ENZYMOL., vol. 100, 1983, pages 468 - 500

Cited By (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11168344B2 (en) 2005-03-31 2021-11-09 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
US10011858B2 (en) 2005-03-31 2018-07-03 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
US11046784B2 (en) 2006-03-31 2021-06-29 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
US10934344B2 (en) 2006-03-31 2021-03-02 Chugai Seiyaku Kabushiki Kaisha Methods of modifying antibodies for purification of bispecific antibodies
US12473375B2 (en) 2006-03-31 2025-11-18 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
US9670269B2 (en) 2006-03-31 2017-06-06 Chugai Seiyaku Kabushiki Kaisha Methods of modifying antibodies for purification of bispecific antibodies
US9028821B2 (en) 2006-06-08 2015-05-12 Chugai Seiyaku Kabushiki Kaisha Method of treating an inflammatory disease comprising administering an NR 10 antibody antagonist
US9745378B2 (en) 2006-06-08 2017-08-29 Chugai Seiyaku Kabushiki Kaisha Antibodies that bind to cytokine receptor NR10
US12116414B2 (en) 2007-09-26 2024-10-15 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in CDR
US12122840B2 (en) 2007-09-26 2024-10-22 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in CDR
US9828429B2 (en) 2007-09-26 2017-11-28 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in CDR
US9688762B2 (en) 2007-09-26 2017-06-27 Chugai Sciyaku Kabushiki Kaisha Modified antibody constant region
US11332533B2 (en) 2007-09-26 2022-05-17 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant region
US12600789B2 (en) 2007-09-26 2026-04-14 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant region
EP3415529A1 (en) * 2007-09-26 2018-12-19 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant region
US9096651B2 (en) 2007-09-26 2015-08-04 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in CDR
US11248053B2 (en) 2007-09-26 2022-02-15 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in CDR
CN101952318A (zh) * 2007-12-05 2011-01-19 中外制药株式会社 抗nr10抗体及其应用
US9399680B2 (en) 2007-12-05 2016-07-26 Chugai Seiyaku Kabushiki Kaisha Nucleic acids encoding anti-NR10 antibodies
US8431127B2 (en) 2007-12-05 2013-04-30 Chugai Seiyaku Kabushiki Kaisha Method for treating pruritus comprising administering an NR10 antagonist
CN101952318B (zh) * 2007-12-05 2014-07-09 中外制药株式会社 抗nr10抗体及其应用
US11359194B2 (en) 2008-04-11 2022-06-14 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding two or more antigen molecules repeatedly
US10472623B2 (en) 2008-04-11 2019-11-12 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding two or more antigen molecules repeatedly
US11371039B2 (en) 2008-04-11 2022-06-28 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
US9868948B2 (en) 2008-04-11 2018-01-16 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
US9890377B2 (en) 2008-04-11 2018-02-13 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
US10662245B2 (en) 2008-09-26 2020-05-26 Chugai Seiyaku Kabushiki Kaisha Methods of reducing IL-6 activity for disease treatment
US8562991B2 (en) 2008-09-26 2013-10-22 Chugai Seiyaku Kabushiki Kaisha Antibody molecules that bind to IL-6 receptor
JPWO2010064697A1 (ja) * 2008-12-05 2012-05-10 中外製薬株式会社 抗ｎｒ１０抗体、およびその利用
EP2354161A4 (en) * 2008-12-05 2013-01-02 Chugai Pharmaceutical Co Ltd ANTIBODY AGAINST NR10 AND APPLICATION THEREOF
EP2949672A1 (en) * 2008-12-05 2015-12-02 Chugai Seiyaku Kabushiki Kaisha Anti-nr10 antibody, and use thereof
US10253091B2 (en) 2009-03-19 2019-04-09 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
US9228017B2 (en) 2009-03-19 2016-01-05 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
US10066018B2 (en) 2009-03-19 2018-09-04 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
US10150808B2 (en) 2009-09-24 2018-12-11 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant regions
WO2011055550A1 (ja) 2009-11-05 2011-05-12 国立大学法人大阪大学 自己免疫疾患又はアレルギー治療剤とそのスクリーニング方法
EP3275898A1 (en) 2009-11-05 2018-01-31 Osaka University Therapeutic agent for autoimmune diseases or allergy, and method for screening for the therapeutic agent
EP3378486A2 (en) 2010-01-20 2018-09-26 Chugai Seiyaku Kabushiki Kaisha Stabilized antibody-containing liquid formulations
US11612562B2 (en) 2010-01-20 2023-03-28 Chugai Seiyaku Kabushiki Kaisha Solution preparation containing stabilized antibody
EP4442277A2 (en) 2010-01-20 2024-10-09 Chugai Seiyaku Kabushiki Kaisha Stabilized antibody-containing liquid formulations
EP3892292A2 (en) 2010-01-20 2021-10-13 Chugai Seiyaku Kabushiki Kaisha Stabilized antibody-containing liquid formulations
WO2011090088A1 (ja) 2010-01-20 2011-07-28 中外製薬株式会社 安定化抗体含有溶液製剤
US10022319B2 (en) 2010-01-20 2018-07-17 Chugai Seiyaku Kabushiki Kaisha Stabilized antibody-containing liquid formulations
US10435458B2 (en) 2010-03-04 2019-10-08 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variants with reduced Fcgammar binding
JPWO2011108714A1 (ja) * 2010-03-04 2013-06-27 中外製薬株式会社 抗体定常領域改変体
WO2011143318A3 (en) * 2010-05-11 2012-01-05 Aveo Pharmaceuticals, Inc. Anti-fgfr2 antibodies
US8481688B2 (en) 2010-05-11 2013-07-09 Aveo Pharmaceuticals, Inc. Anti-FGFR2 antibodies
US11891434B2 (en) 2010-11-30 2024-02-06 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
CN103282509A (zh) * 2010-12-28 2013-09-04 中外制药株式会社 动物细胞的培养方法
US20130295613A1 (en) * 2010-12-28 2013-11-07 Chugai Seiyaku Kabushiki Kaisha Animal cell culturing method
WO2012091124A1 (ja) 2010-12-28 2012-07-05 中外製薬株式会社 動物細胞の培養方法
JP6001456B2 (ja) * 2010-12-28 2016-10-05 中外製薬株式会社 動物細胞の培養方法
WO2013012022A1 (ja) 2011-07-19 2013-01-24 中外製薬株式会社 アルギニンアミドまたはその類似化合物を含む安定なタンパク質含有製剤
EP3235557A1 (en) 2011-09-01 2017-10-25 Chugai Seiyaku Kabushiki Kaisha Method for preparing a composition comprising highly concentrated antibodies by ultrafiltration
WO2013031237A1 (en) 2011-09-01 2013-03-07 Chugai Seiyaku Kabushiki Kaisha Method for preparing a composition comprising highly concentrated antibodies by ultrafiltration
US11124576B2 (en) 2013-09-27 2021-09-21 Chungai Seiyaku Kabushiki Kaisha Method for producing polypeptide heteromultimer
EP4671270A2 (en) 2013-12-27 2025-12-31 Chugai Seiyaku Kabushiki Kaisha METHOD FOR THE PURIFICATION OF ANTIBODY WITH A LOW ISOELECTRIC POINT
WO2015099165A1 (ja) 2013-12-27 2015-07-02 中外製薬株式会社 等電点の低い抗体の精製方法
EP4056993A1 (en) 2014-08-20 2022-09-14 Chugai Seiyaku Kabushiki Kaisha Method for measuring viscosity of protein solution
US10774148B2 (en) 2015-02-27 2020-09-15 Chugai Seiyaku Kabushiki Kaisha Composition for treating IL-6-related diseases
US12359001B2 (en) 2015-04-01 2025-07-15 Chugai Seiyaku Kabushiki Kaisha Method for producing polypeptide hetero-oligomer
US11142587B2 (en) 2015-04-01 2021-10-12 Chugai Seiyaku Kabushiki Kaisha Method for producing polypeptide hetero-oligomer
KR20240033097A (ko) 2015-04-14 2024-03-12 추가이 세이야쿠 가부시키가이샤 Il-31 안타고니스트를 유효 성분으로서 함유하는 아토피성 피부염의 예방용 및/또는 치료용 의약 조성물
KR20210145295A (ko) 2015-04-14 2021-12-01 추가이 세이야쿠 가부시키가이샤 Il-31 안타고니스트를 유효 성분으로서 함유하는 아토피성 피부염의 예방용 및/또는 치료용 의약 조성물
KR20230043246A (ko) 2015-04-14 2023-03-30 추가이 세이야쿠 가부시키가이샤 Il-31 안타고니스트를 유효 성분으로서 함유하는 아토피성 피부염의 예방용 및/또는 치료용 의약 조성물
US12441804B2 (en) 2015-04-14 2025-10-14 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition for prevention and/or treatment of atopic dermatitis comprising IL-31 antagonist as active ingredient
EP4650370A2 (en) 2015-04-14 2025-11-19 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition for prevention and/or treatment of atopic dermatitis containing il-31 antagonist as active ingredient
US11773173B2 (en) 2015-04-14 2023-10-03 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition for prevention and/or treatment of atopic dermatitis comprising IL-31 antagonist as active ingredient
US10544227B2 (en) 2015-04-14 2020-01-28 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition for prevention and/or treatment of atopic dermatitis comprising IL-31 antagonist as active ingredient
US11649262B2 (en) 2015-12-28 2023-05-16 Chugai Seiyaku Kabushiki Kaisha Method for promoting efficiency of purification of Fc region-containing polypeptide
JP2019504060A (ja) * 2016-01-08 2019-02-14 オンコバイオロジクス，インコーポレイティド モノクローナル抗体のアイソフォームを分離するための方法
US11780908B2 (en) 2016-09-16 2023-10-10 Chugai Seiyaku Kabushiki Kaisha Anti-dengue virus antibodies, polypeptides containing variant FC regions, and methods of use
US10604561B2 (en) 2016-09-16 2020-03-31 Chugai Seiyaku Kabushiki Kaisha Anti-dengue virus antibodies, polypeptides containing variant Fc regions, and methods of use
US10844113B2 (en) 2016-09-16 2020-11-24 Chugai Seiyaku Kabushiki Kaisha Anti-dengue virus antibodies, polypeptides containing variant Fc regions, and methods of use
US12187786B2 (en) 2016-09-16 2025-01-07 Chugai Seiyaku Kabushiki Kaisha Anti-dengue virus antibodies, polypeptides containing variant Fc regions, and methods of use
US11851486B2 (en) 2017-05-02 2023-12-26 National Center Of Neurology And Psychiatry Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils
US12509511B2 (en) 2017-05-02 2025-12-30 National Center Of Neurology And Psychiatry Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils
US11891432B2 (en) 2018-03-15 2024-02-06 Chugai Seiyaku Kabushiki Kaisha Anti-dengue virus antibodies having cross-reactivity to Zika virus and methods of use
WO2019225568A1 (ja) 2018-05-21 2019-11-28 中外製薬株式会社 ガラス容器に封入された凍結乾燥製剤
WO2019230725A1 (ja) 2018-05-28 2019-12-05 中外製薬株式会社 充填ノズル
JP2021091704A (ja) * 2019-11-20 2021-06-17 中外製薬株式会社 抗体含有製剤
US11723976B2 (en) 2019-11-20 2023-08-15 Chugai Seiyaku Kabushiki Kaisha Methods of administering anti-IL31A antibody-containing formulations
US11260125B2 (en) 2019-11-20 2022-03-01 Chugai Seiyaku Kabushiki Kaisha Anti-IL31RA antibody-containing formulations
JP2022116305A (ja) * 2019-11-20 2022-08-09 中外製薬株式会社 抗体含有製剤
JP6845973B1 (ja) * 2019-11-20 2021-03-24 中外製薬株式会社 抗体含有製剤
WO2021100794A1 (ja) 2019-11-20 2021-05-27 中外製薬株式会社 抗体含有製剤
JP7675049B2 (ja) 2019-11-20 2025-05-12 中外製薬株式会社 抗体含有製剤
KR20220098046A (ko) 2019-11-20 2022-07-08 추가이 세이야쿠 가부시키가이샤 항체 함유 제제
JP2021169448A (ja) * 2019-11-20 2021-10-28 中外製薬株式会社 抗体含有製剤
KR20210064112A (ko) 2019-11-20 2021-06-02 추가이 세이야쿠 가부시키가이샤 항체 함유 제제
TWI860426B (zh) * 2019-11-20 2024-11-01 日商中外製藥股份有限公司 含有抗體之製劑
US12171830B2 (en) 2019-11-20 2024-12-24 Chugai Seiyaku Kabushiki Kaisha Anti-IL-31RA antibody-containing formulations
US12558423B2 (en) 2020-05-29 2026-02-24 Chugai Seiyaku Kabushiki Kaisha Antibody-containing formulation
WO2022025030A1 (ja) 2020-07-28 2022-02-03 中外製薬株式会社 新規改変型抗体を含む、針シールドを備えた針付プレフィルドシリンジ製剤
WO2022049614A1 (ja) 2020-09-01 2022-03-10 中外製薬株式会社 Ｉｌ－３１アンタゴニストを有効成分として含有する、透析そう痒症の予防用及び／又は治療用医薬組成物
WO2023058723A1 (ja) 2021-10-08 2023-04-13 中外製薬株式会社 プレフィルドシリンジ製剤の調製方法
JP2023159309A (ja) * 2021-12-22 2023-10-31 中外製薬株式会社 生物活性が低下した抗体バリアント
WO2023120561A1 (ja) * 2021-12-22 2023-06-29 中外製薬株式会社 生物活性が低下した抗体バリアント
EP4455163A4 (en) * 2021-12-22 2025-12-24 Chugai Pharmaceutical Co Ltd REDUCED BIOLOGICALLY ACTIVE ANTIBODY VARIANT
JPWO2023120561A1 (ja) * 2021-12-22 2023-06-29
KR20240117039A (ko) 2021-12-22 2024-07-31 추가이 세이야쿠 가부시키가이샤 생물 활성이 저하된 항체 배리언트
KR20260007630A (ko) 2021-12-22 2026-01-14 추가이 세이야쿠 가부시키가이샤 생물 활성이 저하된 항체 배리언트
JP7812826B2 (ja) 2021-12-22 2026-02-10 中外製薬株式会社 生物活性が低下した抗体バリアント
WO2023210670A1 (ja) 2022-04-26 2023-11-02 中外製薬株式会社 医薬製剤含有フィルター内蔵シリンジ
WO2024214811A1 (ja) 2023-04-14 2024-10-17 中外製薬株式会社 タンパク質含有医薬製剤の安定化方法

Also Published As

Publication number Publication date
EP3095862B1 (en) 2020-09-16
MX337081B (es) 2016-02-10
ES2585480T3 (es) 2016-10-06
DK2236604T3 (en) 2016-10-03
ES2834741T3 (es) 2021-06-18
KR20170122860A (ko) 2017-11-06
US20240294653A1 (en) 2024-09-05
JP5682995B2 (ja) 2015-03-11
RU2010127292A (ru) 2012-01-10
CN101939424A (zh) 2011-01-05
TW200932266A (en) 2009-08-01
KR101840994B1 (ko) 2018-03-21
EP2236604B1 (en) 2016-07-06
EP3095862B9 (en) 2021-04-14
EP2236604A4 (en) 2012-08-01
AU2009323249C1 (en) 2026-02-12
US8575317B2 (en) 2013-11-05
AU2009323249B2 (en) 2012-04-19
US9399680B2 (en) 2016-07-26
US20110129459A1 (en) 2011-06-02
KR101643005B1 (ko) 2016-07-28
AU2008332271C1 (en) 2014-04-24
TWI548418B (zh) 2016-09-11
AU2009323249A1 (en) 2010-06-10
US20230183363A1 (en) 2023-06-15
US20110229459A1 (en) 2011-09-22
US20140039165A1 (en) 2014-02-06
EP3095862A1 (en) 2016-11-23
MY177564A (en) 2020-09-20
MX2010006096A (es) 2010-08-04
JPWO2009072604A1 (ja) 2011-04-28
US20150175704A1 (en) 2015-06-25
TW201634479A (zh) 2016-10-01
CN101952318B (zh) 2014-07-09
MX2010007936A (es) 2010-08-16
CA2708532C (en) 2018-06-05
KR20100097721A (ko) 2010-09-03
CN101939424B (zh) 2016-12-28
AU2008332271B2 (en) 2013-11-07
RU2531521C2 (ru) 2014-10-20
BRPI0821110A2 (pt) 2015-07-07
US20200002429A1 (en) 2020-01-02
AU2008332271A1 (en) 2009-06-11
HUE025958T2 (en) 2016-05-30
KR20160074019A (ko) 2016-06-27
BRPI0821110B1 (pt) 2021-04-20
HRP20151215T1 (hr) 2015-12-04
BRPI0821110B8 (pt) 2021-05-25
CN101952318A (zh) 2011-01-19
CA2710264A1 (en) 2010-06-10
CA2710264C (en) 2014-10-07
CA2708532A1 (en) 2009-06-11
EP2236604A1 (en) 2010-10-06

Similar Documents

Publication Publication Date Title
WO2009072604A1 (ja) 抗nr10抗体、およびその利用
WO2006078287A3 (en) Pde4b inhibitors and uses therefor
WO2010060937A3 (en) Pharmaceutical combination comprising a hsp 90 inhibitor and a mtor inhibitor
WO2007127263A3 (en) Therapeutic uses of urolithins
MX2009006536A (es) Compuestos de heteroaril-heteroarilo como inhibidores de cdk para el tratamiento de cancer, inflamacion e infecciones virales.
BRPI0818366A2 (pt) Composto, pró-droga, medicamento, método inibidor de faah, métodos de profilaxia ou tratamento para ansiedade, ou depressão, ou de alívio da dor, e de profilaxia ou tratamento para dor inflamatória ou dor neuropática, e, uso do composto.
WO2007115305A3 (en) Oral dosage forms including an antiplatelet agent and an acid inhibitor
TNSN08400A1 (en) Organic compounds and their uses
WO2007038459A3 (en) Carboxyamine compounds and their use in the treatment of hdac dependent diseases
WO2007038551A3 (en) Use of ibudilast for treating drug and behavioral addictions
WO2005074375A3 (en) Heparanase inhibitors and uses thereof
WO2007121125A3 (en) Hcv inhibitors
WO2008067982A3 (en) Use of carrageenan for treating rhinovirus infections
WO2002060374A3 (en) Benz-1,3-azole derivatives and their uses as heparanase inhibitors
WO2007106915A8 (en) Antibodies to egfl7 and methods for their use
WO2009041663A1 (ja) 皮膚疾患の予防及び／または治療剤
MX2011009100A (es) Anticuerpo humanizado pcrv que tiene actividad anti-pseudomonal.
EA200900073A1 (ru) КОМБИНАЦИЯ ИНГИБИТОРОВ HMG-CoA-РЕДУКТАЗЫ И ИНГИБИТОРОВ ФОСФОДИЭСТЕРАЗЫ 4, ПРЕДНАЗНАЧЕННАЯ ДЛЯ ЛЕЧЕНИЯ ВОСПАЛИТЕЛЬНЫХ ЗАБОЛЕВАНИЙ ЛЕГКИХ
PT2056805E (pt) Utilização de derivados de 2,5-di-hidroxibenzeno para o tratamento de reacção tecidular
TNSN08496A1 (en) Aminothiazoles and their uses
MY154715A (en) Anti-nr10 antibody and use thereof
NL1028599A1 (nl) Verbindingen voor de behandeling van ziekten.
WO2008127382A3 (en) Computational design of ribozymes
WO2007147868A3 (en) Prevention of muscle atrophy
WO2007051785A3 (en) Use of sdf-1 for the treatment and/or prevention of neurological diseases

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880126539.4

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08857126

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2009544736

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 3945/DELNP/2010

Country of ref document: IN

Ref document number: 12010501289

Country of ref document: PH

Ref document number: MX/A/2010/006096

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2708532

Country of ref document: CA

Ref document number: 2008332271

Country of ref document: AU

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2008332271

Country of ref document: AU

Date of ref document: 20081205

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20107014698

Country of ref document: KR

Kind code of ref document: A

REEP Request for entry into the european phase

Ref document number: 2008857126

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2010127292

Country of ref document: RU

Ref document number: 2008857126

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: PI 2010002565

Country of ref document: MY

WWE Wipo information: entry into national phase

Ref document number: 12745781

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0821110

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20100604